Grant: Engage Grants Program
York University
$25,000.00
Detailed structural characterization of the interaction between intrinsically disordered, amyloidogenic proteins and neurodegenerative disease drug candidates
FY 2016-17
Summary
Neurodegenerative diseases like Alzheimer's and Parkinson's may seem very different in terms of symptomology and even the damage done to brain tissue, however, at the molecular level, precisely the same thing has gone wrong: A protein that is normally a critical part of the intricate network that controls cellular function has misfolded and clumped together, forming large aggregates called 'amyloids'. Amyloids have long been a target of those seeking to develop drugs for a host of neurodegenerative diseases, but understanding amyloid formation at it's earliest stages has been challenging. This is because many of the proteins that become amyloidogenic in neurodegenerative disease are 'intrinsically disordered', meaning that they lack a highly specific 'native' structure, which makes them exceptionally difficult to study. The Wilson group at York University has developed a unique technology called Time-resolved Electrospray Ionization Mass Spectrometry with Hydrogen / Deuterium Exchange (TRESI-HDX) that allows for direct measurement of the 'structural biases' that drive function and pathogensis in intrinsically disordered proteins. In the current project, the Wilson group will engage with Treventis corporation, a Canadian anti-amyloid drug maker, to explore the structural consequences of interactions between amyloidogenic proteins and and anti-amyloid drugs.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
492095-2015
Name nom
Wilson, Derek
Department département
Chemistry
Organization id
38
Institution établissement
York University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
Detailed structural characterization of the interaction between intrinsically disordered, amyloidogenic proteins and neurodegenerative disease drug candidates
Keyword
NSERC
Application summary
Neurodegenerative diseases like Alzheimer's and Parkinson's may seem very different in terms of symptomology and even the damage done to brain tissue, however, at the molecular level, precisely the same thing has gone wrong: A protein that is normally a critical part of the intricate network that controls cellular function has misfolded and clumped together, forming large aggregates called 'amyloids'. Amyloids have long been a target of those seeking to develop drugs for a host of neurodegenerative diseases, but understanding amyloid formation at it's earliest stages has been challenging. This is because many of the proteins that become amyloidogenic in neurodegenerative disease are 'intrinsically disordered', meaning that they lack a highly specific 'native' structure, which makes them exceptionally difficult to study. The Wilson group at York University has developed a unique technology called Time-resolved Electrospray Ionization Mass Spectrometry with Hydrogen / Deuterium Exchange (TRESI-HDX) that allows for direct measurement of the 'structural biases' that drive function and pathogensis in intrinsically disordered proteins. In the current project, the Wilson group will engage with Treventis corporation, a Canadian anti-amyloid drug maker, to explore the structural consequences of interactions between amyloidogenic proteins and and anti-amyloid drugs.